FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308399159> ?p ?o ?g. }

• W4308399159 abstract "<h3>Background</h3> Patients with myocarditis secondary to treatment with an immune checkpoint inhibitor (ICI) represent a poor prognosis population with a high unmet clinical need. Data from multiple independent international cohorts have shown that the rate of major adverse cardiac events (MACE) with ICI myocarditis despite administration of corticosteroids ranges from 25-50%. Abatacept is a selective co-stimulation modulator that inhibits T cell activation by binding to CD80 and CD86, thereby blocking its interaction with CD28. In case reports, abatacept has been used to treated ICI myocarditis. The use of abatacept in ICI myocarditis is supported by animal models of ICI myocarditis, with the administration of abatacept leading to a reduction in cardiac immune activation and increased survival. <h3>Methods</h3> The abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM) trial is designed as a phase 3, investigator-initiated, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of abatacept compared to placebo in 390 hospitalized participants with ICI associated myocarditis. Hospitalized participants diagnosed with ICI-related myocarditis, aged ≥18 years, with serum evidence of ongoing myocardial injury (troponin ≥5 times the upper limit normal), and treated, or with intent to treat, with 1000 mg of solumedrol/day are eligible. Participants will receive either abatacept (10 mg/kg) or placebo given IV followed by study drug infusion/placebo again at 24 hours and on day 14 with an optional 4th dose on day 28. The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in MACE among participants hospitalized with myocarditis secondary to an ICI. The primary outcome, MACE, is a composite of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrhythmias, significant bradyarrhythmias, or incident heart failure. Each component of the primary composite end point will be evaluated individually as a secondary endpoint, as are troponin levels, rates of deep venous thrombosis and pulmonary embolism, and incidence rates of treatment-related adverse events. Exploratory outcomes focus on cancer outcomes, healthcare utilization, quality of life, and correlative studies. This study is recruiting at time of submission. Clinical trial information: NCT05335928. <h3>Trial Registration</h3> <h3>NCT05335928</h3> <h3>Ethics Approval</h3> The clinical trial protocol has been approved by the Mass General Brigham Institutional Review Board (Protocol #:2021P003690) and all participants will provide informed consent before taking part." @default.
• W4308399159 created "2022-11-11" @default.
• W4308399159 creator A5035343389 @default.
• W4308399159 creator A5068710430 @default.
• W4308399159 creator A5083431383 @default.
• W4308399159 creator A5087164932 @default.
• W4308399159 creator A5091595592 @default.
• W4308399159 date "2022-11-01" @default.
• W4308399159 modified "2023-09-25" @default.
• W4308399159 title "696 Abatacept for immune checkpoint inhibitor associated myocarditis (ATRIUM): a phase 3, investigator-initiated, randomized, double blind, placebo-controlled trial" @default.
• W4308399159 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0696" @default.
• W4308399159 hasPublicationYear "2022" @default.
• W4308399159 type Work @default.
• W4308399159 citedByCount "0" @default.
• W4308399159 crossrefType "proceedings-article" @default.
• W4308399159 hasAuthorship W4308399159A5035343389 @default.
• W4308399159 hasAuthorship W4308399159A5068710430 @default.
• W4308399159 hasAuthorship W4308399159A5083431383 @default.
• W4308399159 hasAuthorship W4308399159A5087164932 @default.
• W4308399159 hasAuthorship W4308399159A5091595592 @default.
• W4308399159 hasBestOaLocation W43083991591 @default.
• W4308399159 hasConcept C126322002 @default.
• W4308399159 hasConcept C142724271 @default.
• W4308399159 hasConcept C164705383 @default.
• W4308399159 hasConcept C197934379 @default.
• W4308399159 hasConcept C204787440 @default.
• W4308399159 hasConcept C27081682 @default.
• W4308399159 hasConcept C2779338263 @default.
• W4308399159 hasConcept C2779605438 @default.
• W4308399159 hasConcept C2780653079 @default.
• W4308399159 hasConcept C2780875844 @default.
• W4308399159 hasConcept C2908647359 @default.
• W4308399159 hasConcept C71924100 @default.
• W4308399159 hasConcept C99454951 @default.
• W4308399159 hasConceptScore W4308399159C126322002 @default.
• W4308399159 hasConceptScore W4308399159C142724271 @default.
• W4308399159 hasConceptScore W4308399159C164705383 @default.
• W4308399159 hasConceptScore W4308399159C197934379 @default.
• W4308399159 hasConceptScore W4308399159C204787440 @default.
• W4308399159 hasConceptScore W4308399159C27081682 @default.
• W4308399159 hasConceptScore W4308399159C2779338263 @default.
• W4308399159 hasConceptScore W4308399159C2779605438 @default.
• W4308399159 hasConceptScore W4308399159C2780653079 @default.
• W4308399159 hasConceptScore W4308399159C2780875844 @default.
• W4308399159 hasConceptScore W4308399159C2908647359 @default.
• W4308399159 hasConceptScore W4308399159C71924100 @default.
• W4308399159 hasConceptScore W4308399159C99454951 @default.
• W4308399159 hasLocation W43083991591 @default.
• W4308399159 hasOpenAccess W4308399159 @default.
• W4308399159 hasPrimaryLocation W43083991591 @default.
• W4308399159 hasRelatedWork W2056662730 @default.
• W4308399159 hasRelatedWork W2119590791 @default.
• W4308399159 hasRelatedWork W2304633692 @default.
• W4308399159 hasRelatedWork W2412304529 @default.
• W4308399159 hasRelatedWork W2412783236 @default.
• W4308399159 hasRelatedWork W2415018805 @default.
• W4308399159 hasRelatedWork W2902323492 @default.
• W4308399159 hasRelatedWork W2946919477 @default.
• W4308399159 hasRelatedWork W2987008883 @default.
• W4308399159 hasRelatedWork W4233016836 @default.
• W4308399159 isParatext "false" @default.
• W4308399159 isRetracted "false" @default.
• W4308399159 workType "article" @default.